Table 3.

Phase I and phase II clinical trials of peptide-based therapeutic cancer vaccines in combination with immunological adjuvants currently active or recruiting.

Cancer types	Peptide vaccine	Adjuvants	Phase	Recruitment status	Clinical trials
Breast cancer	ESR1	Montanide ISA and GM-CSF	I	Recruiting (2020–2024)	NCT04270149
	HER-2	GM-CSF	I	Recruiting (2019–2023)	NCT04144023
Colorectal cancer	Multiple peptide PolyPEPI1018 vaccine	Montanide	II	Completed (2018-2019)	NCT03391232
Glioblastoma	Multipeptide and the immune modulator XS15	Montanide ISA-51	I	Recruiting (2021–2024)	NCT04842513
	Telomerase-derived helper peptides (UCPVax)	Montanide ISA-51	II	Recruiting (2020–2023)	NCT04280848
Leukemia	Personalized peptide vaccine	TLR1/2 ligand XS15	I	Recruiting (2020–2024)	NCT04688385
	PD-L1 and PD-L2 peptides	Montanide ISA-51	II	Active, not recruiting (2019–2021)	NCT03939234
	Personalized peptide vaccine	GM-CSF and imiquimod	II	Active, not recruiting (2018–2021)	NCT03559413
Melanoma	Mutated neoantigen peptide (BRAF/CD4 epitopes)	CD40 antibody and poly-ICLC	II	Recruiting (2020–2025)	NCT04364230
	NY-ESO-1 cancer-testis antigen	Encapsulated in PLGA nanoparticle	I	Recruiting (2021-2022)	NCT04751786
	Arginase-1 peptide	Montanide ISA-51	I	Recruiting (2018–2021)	NCT03689192
	Personalized peptide vaccine	CAF09b	II	Recruiting (2018–2022)	NCT03715985
Myeloma	PD-L1	Montanide ISA-51	II	Recruiting (2019–2021)	NCT03850522
Pancreatic cancer	KRAS	Poly-ICLC	I	Not yet recruiting (2021–2025)	NCT05013216
	Neoantigen peptide	Poly-ICLC	I	Recruiting (2019–2023)	NCT03956056
Prostate cancer	PGV001 (multiple peptide)	CDX-301	I	Recruiting (2021–2031)	NCT05010200
	Bcl-xL	CAF09b	I	Recruiting (2018–2021)	NCT03412786
	RV001V	Montanide ISA-51	II	Active, not recruiting (2019–2022)	NCT04114825